Go to navigation
Go to content
Astrazeneca Worldwide
AstraZeneca Worldwide
Search
Main navigation
Home
Our medicines
Diseases and conditions
Community support
Help affording your medicines
Research & development
Healthcare professionals
Careers
About AstraZeneca US
Our company
AZ on the issues
Investors
Corporate responsibility
Newsroom
All news
Corporate news
Financial news
Product news
Research news
Media resources
US web sites
Contact us
You are here
Home
About AstraZeneca US
Newsroom
Research news
The following shows headlines of all research-related news articles published within 12-months, starting from most recent.
Subscribe to RSS news feed
News search
Date
Jul 23, 2008
AstraZeneca and Bristol-Myers Squibb submit New Drug Application in the United States and Marketing Authorization Application in Europe for ONGLYZA™ (saxagliptin) for the treatment of type 2 diabetes
Jun 17, 2008
AstraZeneca and Columbia University Medical Center sign strategic research collaboration to develop novel therapeutics for diabetes and obesity
Jun 7, 2008
ONGLYZA™ (saxagliptin) demonstrated significant reductions in key measures of glucose control in treatment naïve people with type 2 diabetes
May 27, 2008
Study of twins reveals genetic susceptibility to COPD chronic obstructive pulmonary disease
May 19, 2008
New survey reveals Hispanic-Americans are taking steps to better understand and manage GERD
Apr 17, 2008
Washington University in St. Louis and AstraZeneca announce Alzheimer’s research collaboration
Mar 12, 2008
AstraZeneca completes enrollment in two pivotal Phase III studies of the investigational drug vandetanib (ZACTIMA®) in non-small cell lung cancer (NSCLC)
Feb 27, 2008
AstraZeneca provides update on cediranib (RECENTIN™, AZD2171) clinical development programme
Jan 24, 2008
M. D. Anderson Cancer Center and AstraZeneca form alliance to advance understanding of cancer-related neuropathic pain
Dec 19, 2007
AstraZeneca and Banner Alzheimer’s Institute collaborate to evaluate new tool targeting Alzheimer’s disease
Nov 30, 2007
AstraZeneca completes enrollment in first Phase III study of the investigational drug vandetanib (ZACTIMA®) in non-small cell lung cancer
Sep 25, 2007
Survival data presented from Phase II study of investigational drug ZD4054 in hormone resistant prostate cancer patients
Sep 20, 2007
Newly published Phase II study shows the investigational drug vandetanib prolongs progression-free survival in patients with advanced non-small cell lung cancer (NSCLC)
Page tools
Print
Bookmark this page
Who is AstraZeneca?
Watch this short video to learn who we are and what we do